Preclinical evaluation of engineered L-asparaginase variants to improve the treatment of Acute Lymphoblastic Leukemia

CONCLUSION: EcA variants demonstrated better pharmacological properties compared to WT that makes them good candidates for further development.PMID:38412663 | DOI:10.1016/j.tranon.2024.101909

Source: Translational Oncology - February 27, 2024 Category: Cancer & Oncology Authors: Soumika Sengupta Mainak Biswas Khushboo A Gandhi Saurabh Kumar Gupta Poonam B Gera Vikram Gota Avinash Sonawane Source Type: research